The weight loss injection Wegovy is now also available as a tablet, but the side effects remain similar and experts warn against excessive expectations of the medication, as a healthy lifestyle is still essential for achieving sustainable weight loss. (translated)
In Germany, the weight loss medication Wegovy is now also available in tablet form, with the article explaining the differences from the injection and important aspects of taking it. (translated)
The introduction of the weight loss pill containing the active ingredient semaglutide in Germany as the first EU country could bring significant changes for society and the approximately twelve million adults with obesity. (translated)
A study by Yale scientists shows that the effectiveness of weight loss medications, such as Ozempic and Wegovy, is no longer solely based on appetite suppression but also depends on the proper functioning of brain cells that induce feelings of hunger. (translated)
Starting from August 31, 2026, patients in Germany can purchase the new weight loss pill Wegovy in pharmacies as a tablet, but will have to bear the costs of up to 278 euros per month themselves, unless there are political changes. (translated)
The daily topics report on August 29, 2026, about the devastating tsunami in the Himalayas that is causing a severe humanitarian crisis, the ongoing airstrikes in the Ukraine conflict, Trump's new oil deal with Venezuela, as well as the risks and opportunities of the weight loss drug Wegovy. (translated)
Pharmig Secretary General Alexander Herzog criticizes the health insurance companies for using incorrect figures regarding medication expenditures and warns of a potential crisis in the European pharmaceutical industry, while emphasizing that discounts are pointless and that high development costs and national differences in price negotiations result in many medications not being brought to market in Austria. (translated)
GLP-1 drugs, such as Ozempic and Wegovy, show unexpected effects, not only limiting appetite and supporting weight loss but also affecting heart health, inflammation, and addiction risk, which requires further research to better understand their full impact on the body. (translated)
Nieuw 'Briefje van Jan' - aan Sophie Hermans "Beste Sophie, Ik geloof zelfs dat Angela de Jong tegenwoordig de redactie van het Algemeen Dagblad niet meer binnengerold hoeft te worden, maar gewoon weer zelf naar binnen kan wandelen..." https://t.co/fzSbhojFPl #ozempic #wegovy #mounjaro #boetes #media #briefjevanjan #media #briefjevanjan #nieuws
The Dutch Health and Youth Inspectorate (IGJ) has imposed fines of tens of thousands of euros on Dutch newspapers, including NRC and de Volkskrant, for overly promotional reporting about the medications Ozempic, Wegovy, and Mounjaro, which the media claims is an infringement on press freedom. (translated)
Dutch media, including NRC, de Volkskrant, AD, and De Telegraaf, have been fined tens of thousands of euros for their reporting on weight loss medications such as Ozempic and Wegovy, as the Health and Youth Care Inspectorate (IGJ) considers these articles to be public advertising, and the editors-in-chief fear that this puts press freedom under pressure. (translated)
In Germany, a new weight loss medication in tablet form containing the active ingredient Semaglutide will be available for the first time starting September 1, 2026, which is approved for weight reduction in individuals with obesity or overweight, although it will only be available by prescription and the costs will initially have to be borne by the patients themselves. (translated)
Matthias Blüher discusses in an interview the newly introduced weight loss tablet Wegovy, which could significantly reduce barriers for patients in obesity treatment, but warns of uncertainties regarding its effects and side effects, and emphasizes the need for prioritized care for high-risk patients in the context of health policy and current legislative barriers in Germany. (translated)
Novo Nordisk presents with the arrival of Wegovy in tablet form, which will be available from September 1 in Germany, a revolution in weight loss for millions of people who are trying to lose weight and prefer an alternative to injections, while discussing effectiveness, daily use, side effects, and the future of treatment. (translated)
GLP-1 drugs, such as Ozempic and Wegovy, not only aid weight loss by reducing appetite, but they can also limit cravings for alcohol and other addictive substances, which is related to their action on brain areas responsible for regulating desires. (translated)
Pharmaceutical company Novo Nordisk will launch Wegovy tablets on the German market on September 1, 2026, which contain the same active ingredient Semaglutide as the currently available injectable forms, thus offering an alternative option for customers who avoid injections. (translated)
The Danish pharmaceutical group Novo Nordisk plans to introduce its weight loss pill Wegovy to the German market, while the company's shares are facing a decline due to investors' disappointment over slightly lower revenues and delays in clinical trials of new drugs. (translated)
The article discusses the possibility that statutory health insurance companies in Germany could start covering the costs of obesity medications like Wegovy and Mounjaro, which are currently considered lifestyle products and are usually paid for by patients themselves, while the new chairwoman of G-BA, Sonja Optendrenk, indicated that it might be reasonable to change regulations and recognize these medications as part of treatment. (translated)
The European Commission has approved the drug Wegovy in tablet form as the first oral medication intended for the treatment of obesity, which is a significant step in the fight against overweight and obesity in the countries of the European Union. (translated)
The European Commission has approved the first oral GLP-1 medication, Wegovy, which aims to help treat obesity and overweight, providing patients with a new, more convenient method of therapy, confirmed by clinical trial results. (translated)
